Status:
UNKNOWN
Development of Biomarker for the Evaluation of Response After Neoadjuvant Therapy in Patients With Pancreatic Cancer
Lead Sponsor:
Asan Medical Center
Conditions:
Genetic Change
Chemotherapy Effect
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
The purpose of this study is to identify and apply biomarkers that can provide better information than previous imaging and blood tests when evaluating the response after neoadjuvant chemotherapy in p...
Detailed Description
BACKGROUND * Pancreatic cancer is a rare cancer of the digestive system, but it is known to have a poor prognosis with a very poor survival rate. Five-year survival rate of all patients with pancreat...
Eligibility Criteria
Inclusion
- The patients who are going to administer neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic cancer
- Performance: 0-2
- No distant metastasis
- Patients who consented to and signed the consent
Exclusion
- Distant metastasis
- Patients included in other clinical studies that may affect this study
- Patients who cannot follow the directions of the researcher
- Patients with moderate or severe comorbidities who are thought to have an impact on quality of life or nutritional status (cirrhosis, chronic kidney failure, heart failure, etc.)
- Pelvic tumor, benign tumor, malignant tumor in other organs
- Patients who received prior chemotherapy
Key Trial Info
Start Date :
July 17 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04110769
Start Date
July 17 2019
End Date
December 31 2023
Last Update
July 20 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan medical center
Seoul, South Korea, 05505